Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to ...

TScan Therapeutics, a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, announced ...

Gordon Brothers in a joint venture with Hilco Consumer - Retail and Tiger Capital Group, began store closing sales at all 869 Big Lots locations. The U.S. closeout retailer is offering up to 25% off ...

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX – Free Report) in a research report sent to investors on Monday morning,RTT News reports. The firm currently has a ...

An update from TScan Therapeutics ( (TCRX) ) is now available.

TScan Therapeutics (TCRX) has entered into a term loan facility with Silicon Valley Bank, a division of First Citizens Bank, for up to $52.5 ...

New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TCRX), a clinical-stage ...

Detailed price information for Tscan Therapeutics Inc (TCRX-Q) from The Globe and Mail including charting and trades.

TScan Therapeutics (NASDAQ:TCRX – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $15.00 ...

The largest stakes include BeiGene, Incyte, ACADIA Pharma, Summit Therapeutics, and Insmed. Notable stake increases in Incyte, Summit Therapeutics, Rhythm Pharma, Kymera Therapeutics, and ...

Ratings for TScan Therapeutics TCRX were provided by 5 analysts in the past three months, showcasing a mix of bullish and ...